Arrowhead Research Corp(NASDAQ:ARWR) announced the earnings results for Fiscal Year 2017 and Q1. The results came in during After-Market on Feb 6, 2017. Earnings per share were $-0.17. The reported EPS was above estimates by 15%. Analysts had estimated an EPS of $-0.2.
Arrowhead Research Corp (ARWR) made into the market gainers list on Tuesdays trading session with the shares advancing 4.26% or 0.08 points. Due to strong positive momentum, the stock ended at $1.96, which is also near the day’s high of $2.15. The stock began the session at $1.93 and the volume stood at 23,14,376 shares. The 52-week high of the shares is $8.22 and the 52 week low is $1.2. The company has a current market capitalization of $146 M and it has 7,45,69,706 shares in outstanding.
Several Insider Transactions has been reported to the SEC. On Oct 18, 2016, Douglas B Given (director) sold 12,000 shares at $6.72 per share price.Also, On Aug 24, 2016, Kenneth Allen Myszkowski (Chief Financial Officer) sold 20,000 shares at $8.00 per share price.On Jan 14, 2015, Mauro Ferrari (director) purchased 2,300 shares at $6.90 per share price, according to the Form-4 filing with the securities and exchange commission.
Arrowhead Research Corporation is a biopharmaceutical company. The Company is engaged in developing RiboNucleic Acid interference (RNAi) therapeutics. The Company’s products include ARC-520 ARC-521 ARC-AAT ARC-F12 ARC-HIF2 and ARC-LPA. ARC-520 is an RNAi-based therapeutic designed to treat chronic hepatitis B virus (HBV) infection. ARC-AAT is an unlocked nucleobase analog-containing RNAi-based therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. Its Dynamic Polyconjugate platform is an RNAi delivery system that promotes high levels of target gene knockdown. ARC-F12 is an RNAi-based therapeutic designed to reduce the production of factor 12 with the goal of providing a prophylactic treatment for hereditary angioedema and thromboembolic diseases. ARC-LPA is an RNAi-based therapeutic designed to reduce production of apolipoprotein A. ARC-HIF2 is an RNAi-based therapeutic designed to reduce the production of hypoxia-inducible factor 2a.